UnitedHealth Group (UNH)

NYSE · Minnetonka, Minnesota, USA · Founded 1977 · CEO Stephen Hemsley

Valuation summary

$582.45 fair value versus $330.48 in the market, a difference of +76.2%. Rated Strong Buy.

Fair value per share$582.45
Current share price$330.48
Upside / downside+76.2%
Bear case$316.97
Bull case$988.75
Discount rate (WACC)9.2%
Terminal growth2.60%
Market capitalisation$297B
EV / Sales0.7x

About UnitedHealth Group

Founded in 1977 as Charter Med in Minnetonka, Minnesota. Stephen Hemsley returned as CEO in 2025 after the stock's collapse. Two halves: UnitedHealthcare, the largest US health insurer covering employer, individual, Medicare Advantage and Medicaid members; and Optum, which includes Optum Health (employing or affiliating with tens of thousands of physicians), Optum Rx (one of the three big pharmacy benefit managers) and Optum Insight (health data and analytics). The vertical integration between insurer and provider is both its strength and its regulatory vulnerability.

Investment case

  • Vertical integration lets Optum capture margin at multiple points in the same healthcare dollar.
  • The stock fell from $625 to a low near $238 — the de-rating from the 2024-25 crisis has been severe and expectations are now low.
  • Medicare Advantage demographics are a long-duration tailwind as the US population ages.

Key risks

  • Medical cost ratios ran well above expectations through 2025, and the market lost confidence in management's ability to forecast them.
  • Department of Justice scrutiny of Medicare Advantage risk coding is unresolved, and HHS inspector-general audits in September 2026 found $46.9M and $24.4M of overpayments at two UnitedHealthcare plans, which the company disputes.
  • Pharmacy benefit managers are a bipartisan political target, and Optum Rx is one of the three largest.

Recent developments

Revenue by segment

UnitedHealthcare55%
Optum Health24%
Optum Rx18%
Optum Insight3%

Five-year forecast

RevenueFree cash flow
Year 1$462.4B$27.8B
Year 2$477.8B$30.6B
Year 3$493.7B$33.6B
Year 4$510.1B$36.7B
Year 5$527.1B$40.0B

What the street says

Among the most contested large caps in healthcare, but the recovery case gained ground in October 2026: third-quarter adjusted EPS of $4.69 beat as the medical care ratio improved to 88.4%, and the 2026 outlook was raised to at least $20.50. Bulls see a franchise still trading below its historical multiple; bears argue the regulatory and cost-trend problems are structural rather than cyclical.

Comparable companies: MRK · ELV · AZN · COR · MCK · NVS · SYK · TMO

Open the interactive model, price chart and sensitivity grid →